Abstract:Tuberous sclerosis complex (TSC) is a relatively common autosomal dominant genetic disorder affecting 1/14,000–1/6000 Western populations. The incidence of TSC in Chinese population is still unknown although case reports of Chinese TSC patients were documented.[1] The main clinical features of TSC include seizures, mental retardation, and the development of hamartomas in multiple organs such as the skin, brain, lung, heart, and kidney. Indeed, the disease virtually manifests in every organ.[2] Two causative genes for TSC, TSC1 gene on chromosome 9q34 and TSC2 gene on chromosome16p13, have been identified in 1997 and 1993 respectively. Approximately, 70% of cases of TSC are de novo mutations.[3] Chinese TSC patients are more likely to have TSC2 missense and frame shift mutations. Here, we record one Chinese TSC family and it is novel frame shift mutation of TSC2. One TSC family was identified through a proband from Sichuan province of China. The proband, a 16-year-old male, first presented with frequent focal motor seizures at age of 6 years and was clinically diagnosed as TSC at age of 9 years. Physical examination found forehead fibrous plaque, facial angiofibromas [Figure 1a], hypopigmented macules, and shagreen patches on his back. [Figure 1b]. He has shown moderate mental retardation and failed to pass any academic examinations. Electroencephalogram (EEG) revealed multifocal spike wave and spike-slow wave complex discharges. Cardiac ultrasound was normal, but renal ultrasound detected multiple small nodular hamartomas. His seizure was successfully controlled by sodium valproate and oxcarbazepine. The father of the proband is 48-years-old without epilepsy or mental retardation. However, physical examination revealed facial angiofibromas, shagreen patches on his back, and confetti-like hypopigmented patches on his legs. Renal ultrasound revealed multiple hamartomas obviously larger than the proband. The third patient of the family was the younger brother of the proband. He was born when the proband was 11-year-old without any prenatal molecular diagnosis. At the age of 1 month, he began to experience frequent focal motor seizures, which could not be controlled by the combined treatment of sodium valproate, oxcarbazepine and topiramate, and demonstrated severe mental retardation. Physical examination was almost the same as the proband. EEG revealed focal and generalized epileptiform discharges. Multiple cardiac rhabdomyoma [Figure 1c] and nodular renal hamartomas were identified by ultrasound. In all the three patients, brain computed tomography showed multiple subependymal calcifications [Figure 1d] and brain magnetic resonance imaging detected multiple cortical tubers as well as subependymal nodules along the lateral walls of the lateral ventricles [Figure 1e and f].Figure 1: (a) Forehead fibrous plaque and facial angiofibromas of the proband. (b) Shagreen patches on the back of the proband. (c) Heart ultrasound of the younger brother detects multiple cardiac rhabdomyoma. (d) Brain computed tomography of the father shows multiple subependymal calcifications. (e) Brain magnetic resonance imaging (MRI) of the proband reveals subependymal nodules along the lateral walls of the lateral ventricles. (f) Brain MRI of the proband demonstrates multiple cortical tubers.According to the Diagnostic Criteria of the National Institutes of Health Consensus Conference, the presence of two major features or one major and two minor features is sufficient for definitive diagnosis of TSC. In this family, each patient presented more than two major features. Therefore, all the three patients had a definite clinical diagnosis of TSC. This study was approved without restrictions by Medical Ethics Committee of Sichuan University, and informed consents were obtained from the patients or their parents. Blood (3 ml) was drawn for Sanger sequencing from the patients, their healthy family members, and 100 unrelated normal controls. By sequencing the polymerase chain reaction fragments of the entire coding region and the exon-intron boundaries of TSC1 and TSC2, we detected a novel frame-shift mutation (c. 3576_3577insA) in the TSC2 gene exon 29 in each of the three patients [Figure 2a]. The mutation was not observed in other healthy family members and the unrelated normal controls [Figure 2b].Figure 2: (a) DNA sequencing of exon 29 of the tuberous sclerosis complex (TSC2) gene finds a c. 3576_3577insA mutation in three patients. (b) Sequence of exon 29 of the TSC2 gene in normal subjects.Tuberous sclerosis complex 1 and TSC2 genes, the pathogenic genes of TSC, are indicated as tumor suppressor genes due to their function in regulation of cell growth and differentiation by inhibiting the mammalian target of rapamycin (mTOR) in the Akt-mTOR-S6kinase cell growth pathway. Mutations including nonsense mutations, small deletions, splice site changes, missense mutations, and sometimes large deletions or rearrangements can occur over the entire regions of TSC1 and TSC2. However, no hotspots have been found.[3] In this report, the family had a frame-shift mutation (c. 3576_3577insA) in exon 29 of TSC2 gene detected by Sanger sequencing, the gold standard to detect gene mutations. The fact that this mutation was observed only in the patients of the family but not in other healthy family members and the 100 unrelated normal controls suggests that this mutation is pathogenic. This mutation cannot be found in the leiden open variation database, suggesting the sequence aberration is novel. Gene mutations often cause essential alterations of its coded protein. The product of TSC2 gene, tuberin, which consists of 1807 amino acids, is known to have seven domains including a leucine zipper region, two small coiled-coil domains (CCD1, CCD2), a small region of similarity with GTPase-activating protein (GAPD), two transcriptional activation domains (TAD1, TAD2), and a calmodulin-binding site (CaMD) in the carboxyl terminus of tuberin. The GAP activity of tuberinis thought to be essential for its physiological function. GAPD of tuberin activates GTPase, reducing stimulation of ras homologue enriched in brain and its downstream protein mTOR.[4] The frame-shift mutation (c. 3576_3577insA) of TSC2 in the family is predicted to truncate the TSC2 protein by 614 amino acids and add 39 amino acids, resulting in an alternative protein that lacks four of the seven domains: TAD1, GAPD, TAD2, and CaMD. The alternated tuberin could not effectively act the function of tumor suppressor gene when combined with hamartin, thus causing uncontrolled cell growth and tumorigenesis. Tuberous sclerosis complex patients with the same genotype can have different clinical phenotypes.[5] In this family, patients are characterized by similar physical examination with different severity of symptoms. On one hand, the three patients had almost the same major features of TSC and the shagreen patches of the proband and his brother was nearly at the same position on the back. While some other features of TSC, such as non-traumatic ungula or periungual fibroma, were absent in the family. Consequently, it is probable that the same inheritable mutation of TSC has caused similar manifestations among family members. On the other hand, in each patient, the severity of the disease is completely different. The symptoms of the father are almost absent, whereas the third son, the proband's little brother with TSC, are most severe, and the proband are between them. The phenomenon of mosaicism can explain the difference in severity between the father and his children, but cannot explain that between the two children. Therefore, whether TSC caused by the same mutation would aggravate itself when transmitted to the next generation and result in severity differences between siblings needs to be further explored.

Abstract:Chest computed tomography (CT) screening is becoming more popular in China. Therefore, more and more rare diseases and early stages of lung diseases were found. Here, we reported a case who presented as multiple ground glass nodules incidentally found in chest CT scan who had been suspected as synchronous multiple primary lung cancer (SMPLC) and/or metastatic cancer. She was finally diagnosed as tuberous sclerosis complex (TSC), an autosomal-dominant disorder characterized by the formation of hamartomatous lesions in the skin, eyes, kidney, and central nervous system.[12] Tuberous sclerosis complex 1 (TSC1)gene mutation (c.1030-1G>A) was found in her and her family members. This is a very rare report in China. A 37-year-old woman was referred to our institution for multiple bilateral ground glass nodules from 1 mm to 5 mm in diameter found in an incidental chest CT scan on April 12, 2016 [Figure 1a]. She had no complaint and suspected as SMPLC and/or metastasis cancer in the local hospital. The positron emission tomography/CT (PET/CT) was proceeded, showing multiple ground glass nodules on the bilateral lungs and sclerotic bone changes including vertebral bodies, ribs, sternum, and pelvis which revealed normal 18F-deoxyglucose intake [Figure 1b]. We proceeded the transbronchial lung biopsy (TBLB) in different sites of the left lung, including the superior lobe and the outer and posterior basal segments of the inferior lobe, obtaining >20 lung tissue specimens. The pathologic findings revealed that the lesions were multifocal and pneumocyte hyperplasia with atypical epithelial cells [Figure 1c]. She was discharged and followed up since there was no evidence of malignance.Figure 1: Representative images of the patient. (a) First chest computed tomography on April 5, 2016: Multiple bilateral ground glass nodules in chest computed tomography scan (red arrows); (b) sclerotic bone changes in vertebral bodies and pelvis on April 12, 2016 in positron emission tomography/computed tomography (red arrows); (c) histopathological findings of the transbronchial lung biopsy specimen. Multifocal and pneumocyte hyperplasia with atypical epithelial cells (H and E, original magnification, ×200); (d) shagreen patch on dorsolumbar area of back; (e) abnormal signals were found in the right frontal lobe in brain magnetic resonance imaging (red arrow); (f-i) sequencing of tuberous sclerosis complex 1: f (the patient), h (her mother), and i (her son): One splice site mutation (c.1030-1G>A) in intron 10 of tuberous sclerosis complex 1 was detected (red arrow); g (her father) no mutation in tuberous sclerosis complex 1 was detected (red arrow); (j) the family pedigree: the roman numerals at the left side represent generations. III-1 was the case to be reported (red arrow). Tuberous sclerosis complex 1 genetic testing was performed in the index cases (II-2, 3, III-1, IV-1, black and red arrows).Six months later, re-examined PET/CT showed similar lesions on the lung and bones. She reported one episode of “epilepsy” 8 years before for unknown reasons. Some physical signs were found, including hypopigmented macules on her back, right forearm, and right calf, ungual fibromas on her left hand, and shagreen patch on dorsolumbar area of the back [Figure 1d]. Brain magnetic resonance imaging was performed and abnormal signals were found in the left parietal lobe and right frontal lobe [Figure 1e]. Her mother and son showed similar physical signs. The same chest CT manifestations were found in her mother and uncle (her mother's brother). According to these information, TSC family was suspected. TSC1 and TSC2 mutations were further tested. Genomic DNA was extracted from whole blood and formalin-fixed and paraffin-embedded (FFPE) samples of TBLB of the patient, respectively, using the QIAamp DNA Mini Kit (Qiagen Inc., Venlo, The Netherlands) according to the manufacturer's instructions. Customized NimbleGen array (NimbleGen, Roche, USA) was used to capture and enrich 27,000b target region (all exons and flanking 100 bp) of TSC1 and TSC2. Sequencing was performed with IlluminaNextSeq CN500 (Illumina, San Diego, USA). After removing low-quality or adapter contamination reads in the sequencing data, the filtered reads were mapped to the human genome build GRCh37 using BWA (a Burrows-Wheeler aligner). Single nucleotide variant and indel calls were generated using MuTect and GATK, respectively. To verify the mutation detected by target region capture sequencing, we designed primers flanking mutation regions according to gene sequence (NG_005895.1 and NG_012386.1) provided by the NCBI, and then used genome DNA as templates to amplify target region. Sanger sequencing was performed with ABI 3730 DNA Analyzer (Thermo Fisher Scientific, Massachusetts, USA). One splice site mutation (c.1030-1G>A) in intron 10 of TSC1 was detected [Figure 1f] in both blood and FFPE samples. The whole blood samples of her familial members including her mother, father, and son were also examined. The same mutation was detected in her mother and son [Figure 1g–1i]. The family pedigree is shown in Figure 1j. The familial TSCwas determined. Since multifocal micronodular pneumocyte hyperplasia (MMPH) does not appear to be fatal and remained stable,[2] close follow-up was chosen for the patient, her mother, her uncle, and her son. TSC was initially described approximately 150 years ago by von Recklinghausen in 1862. The incidence is approximately 1 in 5000–10,000 births.[2] The presence of common manifestations include cortical or subependymal tubers, white matter abnormalities, cardiac rhabdomyoma, renal angiomyolipoma, and skin lesions. The lungs, digestive system, retroperitoneum, and bone can be less frequently involved.[1] The pulmonary manifestations of TSC include MMPH and lymphangioleiomyomatosis (LAM).[2] MMPH in TSC was first described by Popper et al.[3] in 1991. On high-resolution CT, the MMPH was characterized by multiple nodules ranging in size from 1 mm to 10 mm, scattered throughout the lungs in a random distribution.[1] For the cases presented as MMPH in chest CT as this case, SMPLC or miliary metastatic malignancy must be carefully differentiated. Hence, pathological examination of the nodules in the lung was essential. TSC1 or TSC2 mutation has been regarded as an independent criterion for the diagnosis or prediction of TSC, regardless of the clinical findings.[2] They are indicated as tumor suppressor genes due to their function in the regulation of cell growth and differentiation by inhibiting the mammalian target of rapamycin (mTOR) in the Akt-mTOR-S6kinase cell growth pathway.[4] A “pathogenic” mutation was defined as a mutation that clearly prevents protein synthesis and/or inactivates the function of the TSC1 or TSC2 proteins.[2] The mutation in intron 10 (c.1030-1G>A) we reported in this case is a splice mutation in TSC1 gene. It does not directly change the encoded amino acid sequence of the TSC1 protein. However, this variant affected splice acceptor site directly, thus it might interrupt the recognition of spliceosomes and result in incorrect splicing. This mutation was first reported in a familial TSC by Niida et al.[5] in 1999. However, this report did not provide the family pedigree. To our knowledge, this is a very rare report regarding the c.1030-1G>A mutation in a family TSC pedigree in China. The clinical diagnostic criteria of TSC include 11 major features and six minor features according to the 2012 International Tuberous Sclerosis Complex Diagnostic Criteria.[2] Some features appeared only at birth or infancy. Lesions such as hypomelanotic macules are the major features observed in about 90% of individuals with TSC which could be ignored by clinicians due to limited knowledge about TSC. Hypopigmented macules, ungual fibromas, and shagreen patch found in this case had been neglected for a long time, causing the delay of diagnosis. TSC presented as MMPH was reported having better prognosis and specified treatment was usually unnecessary since the patients were usually asymptomatic and remained stable for a long time. Long-term follow-up is reasonable for this case and her family. In conclusion, TSC presented as MMPH is a rare disease, and further examinations should be performed when multiple ground glass nodules were found in chest CT scan. The mutation in intron 10 (c.1030-1G>A) of TSC1 might indicate a pathogenetic mechanism which could be beneficial for differential diagnosis and future therapy exploring. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s)/patient's guardians has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patient(s)/patient's guardians understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship The study was supported by a grant from the key project of Nanjing Public Health Bureau (No. ZKX15020). Conflicts of interest There are no conflicts of interest. Acknowledgment We would like to thank Aukur Sharan for his language polishing of the manuscript.

A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway

[Analysis of Gene Mutation in Patients with Tuberous Sclerosis Complex with Polymerase Chain Reaction-Single Strand Conformation Polymorphism].

[Genetic Analysis of a Mosaic Case with Low Proportion Mutation of TSC2 Gene].

[Genetic Analysis of a Pedigree Affected with Tuberous Sclerosis Complex Caused by a Novel Mutation of TSC1].

A novel TSC1 frameshift mutation c.1550_1551del causes tuberous sclerosis complex by aberrant splicing and nonsense-mediated mRNA degradation (NMD) simultaneously in a Chinese family

TSC1 intragenic deletion transmitted from a mosaic father to two siblings with cardiac rhabdomyomas: Identification of two aberrant transcripts

Clinical Characteristics and Genetic Analysis of a Chinese Pedigree Affected with Tuberous Sclerosis Complex

A case of tuberous sclerosis induced by a somatic mosaic mutation in the TSC2 gene

Identification of a novel TSC1 variant in a family with developmental and epileptic encephalopathies: A case report and literature review

Two Novel TSC2 Mutations in Pediatric Patients with Tuberous Sclerosis Complex: Case Report.

A Chinese Tuberous Sclerosis Complex Family and a Novel Tuberous Sclerosis Complex-2 Mutation.

[Analysis of Clinical Features and Genetic Variants in a Chinese Pedigree Affected with Tuberous Sclerosis].

Biallelic Mutations in TSC2 Lead to Abnormalities Associated with Cortical Tubers in Human iPSC-Derived Neurons

Genotype and Phenotype Analysis of Chinese Children with Tuberous Sclerosis Complex: A Pediatric Cohort Study.

Identification of TSC2 mosaic mutation limited to cortical tuber with TSC targeted sequencing: a case report and literature review

Analysis of phenotypic heterogeneity in a family with tuberous sclerosis complex

Human TSC2 Mutant Cells Exhibit Aberrations in Early Neurodevelopment Accompanied by Changes in the DNA Methylome

Molecular and Functional Assessment of TSC1 and TSC2 in Individuals with Tuberous Sclerosis Complex

Analysis of 5238-5255 del 18 bp and 2713 C>T mutaitons in TSC2 gene in two Chinese patients with tuberous sclerosis complex.

A Tuberous Sclerosis Family with TSC1 (C.1030-1G>a) Mutation Found Through a Female Presenting As Multiple Ground Glass Nodules in Chest Computed Tomography Incidentally

Novel TSC1 and TSC2 Gene Mutations in Chinese Patients with Tuberous Sclerosis Complex.